Metastasis-directed therapy in oligometastatic prostate cancer.

ABSTRACT:

Purpose of review

To summarize the recent findings on the subject of metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (omPCa).

Recent findings

Evidence from two randomized clinical trials (RCTs) and a meta-analysis show favorable toxicity profiles, and the potential to delay androgen-deprivation therapy (ADT) for up to two years in nearly half of patients with metachronous hormone-sensitive omPCa. Another RCT showed promising results of MDT as treatment-escalation method combined with androgen receptor signaling inhibitors (ARSI) in first-line treatment for castration-resistant omPCa.Surveys by radiation oncologists and consensus guidelines advocate for MDT across various omPCa scenarios. Multiple single-arm trials present encouraging res

SUBMITTER: Miszczyk M 

PROVIDER: S-EPMC10990025 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature